{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:11Z","timestamp":1792740731497,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126885","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T09:54:57Z","timestamp":1740045297000},"page":"126885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens"],"prefix":"10.1016","volume":"51","author":[{"given":"Julia L.","family":"McKechnie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kepl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Louth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Weatherly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Feldhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126885_bb0005","series-title":"Invasive meningococcal disease - Annual Epidemiological Report for 2021","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126885_bb0010","article-title":"About meningococcal disease","year":"2024","journal-title":"CDC"},{"key":"10.1016\/j.vaccine.2025.126885_bb0015","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3201\/eid1206.051297","article-title":"Social behavior and meningococcal carriage in British teenagers","volume":"12","author":"MacLennan","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126885_bb0020","first-page":"151","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review","author":"Pardo de Santayana","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.126885_bb0025","author":"Meningitis"},{"key":"10.1016\/j.vaccine.2025.126885_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis","volume":"322","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126885_bb0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.vaccine.2025.126885_bb0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126885_bb0055","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2025.126885_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1514866","article-title":"Immunogenicity of a meningococcal B vaccine during a university outbreak","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126885_bb0065","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14760584.2022.2064850","article-title":"Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126885_bb0070","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","article-title":"Correlates of protection for meningococcal surface protein vaccines: lessons from the past","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126885_bb0075","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126885_bb0080","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126885_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0154-0","article-title":"Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine","volume":"5","author":"Harris","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126885_bb0090","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126885_bb0095","first-page":"136","article-title":"Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data","volume":"84","author":"Lucidarme","year":"2022","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.126885_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz Garc\u00eda","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126885_bb0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126885_bb0110","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","article-title":"Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses","volume":"56","author":"Ols","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126885_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126885_bb0120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126885_bb0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.aat9120","article-title":"Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers","volume":"363","author":"Tokatlian","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126885_bb0130","doi-asserted-by":"crossref","first-page":"eabn8934","DOI":"10.1126\/science.abn8934","article-title":"Low protease activity in B cell follicles promotes retention of intact antigens after immunization","volume":"379","author":"Aung","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126885_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110217","article-title":"Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens","volume":"38","author":"Read","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.126885_bb0140","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.vaccine.2020.03.001","article-title":"An assessment of the use of hepatitis B virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis","volume":"38","author":"Aston-Deaville","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126885_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273322","article-title":"Self-assembling protein nanoparticles and virus like particles correctly display \u03b2-barrel from meningococcal factor H-binding protein through genetic fusion","volume":"17","author":"Cappelli","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126885_bb0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1126\/science.aaf8818","article-title":"Accurate design of megadalton-scale two-component icosahedral protein complexes","volume":"353","author":"Bale","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126885_bb0155","article-title":"Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever","volume":"13","author":"Lacasta","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126885_bb0160","article-title":"Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1\/2 trial","volume":"51","author":"Song","year":"2022","journal-title":"E Clinical Med"},{"key":"10.1016\/j.vaccine.2025.126885_bb0165","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial","volume":"64","author":"Song","year":"2023","journal-title":"E Clinical Med"},{"key":"10.1016\/j.vaccine.2025.126885_bb0170","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-9202-7_12","article-title":"Meningococcal serogroup a, B, C, W, X, and Y serum bactericidal antibody assays","volume":"1969","author":"Lucidarme","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2025.126885_bb0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/srep00341","article-title":"A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp","volume":"2","author":"Vu","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126885_bb0180","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1128\/CVI.00103-10","article-title":"Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding","volume":"17","author":"Beernink","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126885_bb0185","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/IAI.00367-08","article-title":"Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein","volume":"76","author":"Beernink","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126885_bb0190","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.molimm.2009.02.021","article-title":"A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups","volume":"46","author":"Beernink","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2025.126885_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.0300-9475.2004.01362.x","article-title":"The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis","volume":"59","author":"Michaelsen","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2025.126885_bb0200","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.vaccine.2022.04.101","article-title":"A comparison of national vaccination policies to prevent serogroup B meningococcal disease","volume":"40","author":"Sulis","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126885_bb0205","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126885_bb0210","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2010.11.064","article-title":"Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1","volume":"29","author":"Brunelli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126885_bb0215","first-page":"5","article-title":"Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI","author":"Kelly","year":"2020","journal-title":"Insight"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:39:20Z","timestamp":1745357960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"alternative-id":["S0264410X25001823"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126885","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126885"}}